ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CTO Tclarke Plc

158.50
0.50 (0.32%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tclarke Plc LSE:CTO London Ordinary Share GB0002015021 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 0.32% 158.50 158.00 158.50 159.00 158.00 158.00 102,099 16:35:21
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Special Trade Contractor,nec 491M 6.5M 0.1230 12.93 84.03M
Tclarke Plc is listed in the Special Trade Contractor sector of the London Stock Exchange with ticker CTO. The last closing price for Tclarke was 158p. Over the last year, Tclarke shares have traded in a share price range of 105.00p to 167.50p.

Tclarke currently has 52,850,780 shares in issue. The market capitalisation of Tclarke is £84.03 million. Tclarke has a price to earnings ratio (PE ratio) of 12.93.

Tclarke Share Discussion Threads

Showing 4901 to 4924 of 5125 messages
Chat Pages: 205  204  203  202  201  200  199  198  197  196  195  194  Older
DateSubjectAuthorDiscuss
08/3/2023
10:38
Cenkos comment:-

 Outlook and view: There is strong growth momentum with the group at present,
with significant opportunities in data centres, healthcare and increasingly energy
efficient smart building solutions. It remains focused on delivering its growth
strategy and looks to be well on track to deliver its target of achieving turnover of
£500m by the end of 2023. Whilst the share price has enjoyed a recovery YTD, a
headline FY23E EV/EBITDA of sub 5x does not appear to reflect the clear growth
trajectory at present or the strength of its market position. BUY.

cwa1
08/3/2023
10:16
They have been over 180p in 2021, and they are clearly significantly bigger business now. At that rating they would be north of £2.20; I don't see why that rating could not apply in the future.
edmundshaw
08/3/2023
10:12
They have done well but margins still very tight (like most in the sector) so any hiccups are costly. Not sure it will ever get more highly rated despite their skills and market position.

GLA

petomi
08/3/2023
07:28
all very positive... like the increase in healthcare related work
janeann
08/3/2023
07:10
Excellent results from CTO, and a lovely 10% increase in the dividend. No signs of a recession here...
igoe104
08/3/2023
07:09
Seems to be an issue with the news feed. So I’ll paste this. Looks ok first glance






TClarke delivers record revenues of £426m


TClarke plc ("the Group" or "TClarke"), the Building Services Group, announces its preliminary results for the year ended 31 December 2022.

Financial Highlights

RESULTS FOR THE FULL YEAR ENDED 31 DECEMBER
2022
2021
Change
Revenue
£426.0m
£327.1m
+30%
Operating profit
£11.5m
£8.8m
+31%
Profit before tax
£10.3m
£7.8m
+32%
Basic Earnings per share
19.60p
14.99p
+31%
Net cash at year end
£7.5m
£5.3m
+42%
Total dividend per share
5.35p
4.85p
+10%





FY 2022 summary

· Record results with the Group on course to achieve its strategic target of £500m annual revenue
· Revenue up 30% to £426m
· Operating margin 2.7% (2021: 2.7%)
· Earnings per share up 31% to 19.6p
· Strong balance sheet
· Net Cash £7.5m (2021: £5.3m)
· Average month end cash £2.6m (2021: -£2.9m)
· Net Assets £38.7m (2021: £26.5m)
· High quality and growing forward order book of £555m, up 4% on 2021
· Data centre business expanding rapidly; 2022 revenue £129m (2021: £39m)
· Further progress made in expanding in the healthcare sector, large projects outside London and smart buildings. Total 2022 revenues from these sectors £91m (2021: £51m)
· Progressive dividend policy with total dividend up 10%
· Record intake of 50 Apprentices, with 210 now employed across TClarke
· New target of 25% women in apprenticeship and training roles by 2028
· Total type 1 and 2 emissions fall to 4.8 tCO2e/£m revenue (2021: 5.8 tCO2e/£m revenue)

Mark Lawrence, CEO commented

"2022 has been a transformational year in the history of TClarke with a significant step change in the size of the Group. Our record results reflect the high quality of our operations and talent and commitment of our people and supply chain partners.

The Group is in fantastic shape. We have an excellent order book of high quality projects across a wide range of sectors. The business is supported by our strong balance sheet, which continues to grow, with net assets increasing by 46% compared with 2021. We remain committed to delivering economic, social and environmental value for all our stakeholders and are working towards achieving net zero by 2026.

Looking ahead, we continue to make excellent progress in our chosen markets and our well-positioned to achieve our £500m revenue target in 2023.''

-ends-
T

dr biotech
07/3/2023
15:40
Results tomorrow...
igoe104
31/1/2023
18:47
What are you going to wear?
rbewes
31/1/2023
09:48
The company are doing a zoom webinaer on the 9th March. I've just had my invite.
igoe104
26/1/2023
08:26
Cenkos note update.
igoe104
26/1/2023
08:15
TClarke PLC Trading Statement
johnwise
26/1/2023
08:00
agree looks pretty positive and unfortunateky you are probably right muckshifter
janeann
26/1/2023
07:16
Everything looks good to me. 👍
igoe104
24/11/2022
11:48
If 40 million of revenue has been forwarded to 2023, it will be difficult to see a 18% drop in 2023. Especially when they are forecasting at least 500 Million revenue.🤷
igoe104
24/11/2022
09:54
Where the link for 18% reduction for next year ?
igoe104
24/11/2022
09:27
Agree Dr B..

toswas I hadn't seen that they were reducing 2023 numbers.

edmundshaw
24/11/2022
08:59
I get a bit fed up with companies saying orders retimed/reprogrammed into next year. It’s a miss. Otherwise the target should be 540m for next year.

Having said that, if they can deliver £14m next year(2.8*500m) then the shares are cheap with a 50m mkt cap

dr biotech
24/11/2022
08:41
Agree with most of that edmund but not just a timing issue when the house broker is reducing numbers by 11% this year and 18.5% next!
tiswas
24/11/2022
08:18
In reality its a big profit warning IMO. Its all down to personal opinion whether its in the price or not.
spooky
24/11/2022
08:17
Took my numbers from Stockopedia. Will revert to Cenkos numbers. However business is in good shape with a decent yield imo
aishah
24/11/2022
08:13
FY 23 eps forecast down 18.5% from 24.2p to 19.7p
phar lap
24/11/2022
08:13
No idea where you get your numbers from Aishah. Cenkos forecasting adjusted eps of 19p for '22, down 11%.
tiswas
24/11/2022
08:07
The ONLY thing the market seems to be seeing is the:- with some £40m of revenue previously expected to be delivered in 2022 now being reprogrammed into 2023... comment.

Ho hum...

cwa1
24/11/2022
07:57
Snippet from Cenkos research this morning:-

◼ View: The group remains in a very strong position, targeting a balanced and protected order and a balance sheet supportive of its growth ambitions. On revised forecasts, the shares remain inexpensive on a FY23E PE of c.6x and EV/EBITDA of c.3x. With a 4.5% dividend yield and an improving balance sheet providing a further underpin to the equity story, we reiterate our BUY recommendation.

cwa1
Chat Pages: 205  204  203  202  201  200  199  198  197  196  195  194  Older

Your Recent History

Delayed Upgrade Clock